Showing results (31-40 of 263) with videos related to
Sort By:
Pageof 27
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1994
Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancerP Valagussa, A Moliterni, M Terenziani, et al.Surgery|August 26, 1998
End points in the analysis of breast cancer survival: relapse versus death from tumorM J Edwards, G Bonadonna, P Valagussa, et al.Cancer|June 1, 1977
The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug toleranceG Bonadonna, A Rossi, P Valagussa, et al.Journal of the National Cancer Institute|January 1, 1981
Labeling index as a prognostic marker in non-Hodgkin's lymphomasA Costa, G Bonadonna, E Villa, et al.Seminars in Oncology|March 1, 1986
CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's diseaseA Santoro, S Viviani, P Valagussa, et al.Breast Cancer Research and Treatment|January 1, 1996
Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancyR Demicheli, A Abbattista, R Miceli, et al.Seminars in Oncology|April 1, 1992
ABVD in the treatment of Hodgkin's diseaseV Bonfante, A Santoro, S Viviani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1983
Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cyclesG Tancini, G Bonadonna, P Valagussa, et al.Seminars in Oncology|March 1, 1985
Third-line salvage chemotherapy in Hodgkin's diseaseG Bonadonna, S Viviani, P Valagussa, et al.The New England Journal of Medicine|April 6, 1995
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-upG Bonadonna, P Valagussa, A Moliterni, et al.Pageof 27